Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022)
Inhibikase Therapeutics (IKT) posted quarterly Current Deferred Revenue of $23683.0 for Q3 2022, little changed quarter-over-quarter from $23684.0 in Q2 2022.
Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Current Deferred Revenue for 3 consecutive years, with $23683.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Current Deferred Revenue changed N/A year-over-year to $23683.0; the TTM figure through Sep 2022 stood at $23683.0 (changed N/A YoY), while the FY2020 annual figure was $2.3 million, changed N/A from the prior year.
- Current Deferred Revenue held at $23683.0 in Q3 2022 per IKT's latest filing, from $23684.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $2.3 million in Q4 2020 and bottomed at $23683.0 in Q3 2022.
- Historically, Current Deferred Revenue has averaged $753415.2 across 3 years, with a median of $142619.0 in 2021.
- On a YoY basis, Current Deferred Revenue climbed as much as 83.39% in 2022 and fell as far as 83.39% in 2022.
- Inhibikase Therapeutics' Current Deferred Revenue stood at $2.3 million in 2020, then slumped by 93.87% to $142619.0 in 2021, then tumbled by 83.39% to $23683.0 in 2022.
- Business Quant data shows IKT's Current Deferred Revenue at $23683.0 in Q3 2022, $23684.0 in Q2 2022, and $142619.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 23,683.00 |
| Jun 30, 2022 | 23,684.00 |
| Jun 30, 2021 | 142,619.00 |
| Mar 31, 2021 | 1.25 Mn |
| Dec 31, 2020 | 2.33 Mn |